Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.63 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.61 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186084 | 0.99 | MCHR1 (0.61) | MCHR1MCHR2HTR4LMNASMN1; SMN2 | |
| SCHEMBL1184152 | 0.90 | LMNA (0.70) | MCHR1LMNAKMT2AEPHX2 | |
| SCHEMBL6110012 | 0.82 | EPHX2 (0.74) | MCHR1MCHR2HTR4EPHX2 | |
| SCHEMBL6110214 | 0.81 | MCHR1 (0.90) | MCHR1MCHR2LMNA | |
| SCHEMBL1186358 | 0.81 | HTR4 (0.69) | MCHR1MCHR2HTR4LMNASMN1; SMN2 | |
| SCHEMBL6109760 | 0.81 | EPHX2 (0.75) | MCHR1MCHR2EPHX2 | |
| SCHEMBL6109144 | 0.81 | MCHR1 (0.68) | MCHR1MCHR2HTR4LMNAEPHX2 | |
| SCHEMBL6107774 | 0.80 | MCHR1 (0.88) | MCHR1MCHR2LMNA | |
| SCHEMBL1186894 | 0.80 | HPGD (0.58) | MCHR1MCHR2SMN1; SMN2ALDH1A1DRD2 | |
| SCHEMBL6109359 | 0.80 | MCHR1 (0.90) | MCHR1MCHR2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-02-27 | — | — | US | claimed |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2021-09-30 | — | — | US | claimed |
| EP-3837008-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | claimed |
| CN-112703036-A | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2021-04-23 | — | — | CN | claimed |
| WO-2020035555-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | claimed |
| EP-3837008-B1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-09-24 | — | — | EP | disclosed |
| CN-112703036-B | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-02-27 | — | — | US | disclosed |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2021-09-30 | — | — | US | disclosed |
| EP-3837008-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | disclosed |
| CN-112703036-A | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2021-04-23 | — | — | CN | disclosed |
| WO-2020035555-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | disclosed |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-03-03 | — | — | US | disclosed |
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-02-03 | — | — | US | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2009-01-08 | — | — | US | disclosed |
| US-7427390-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | SCHERING AG (DE) | 2008-09-23 | — | — | US | disclosed |
| EP-1722827-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | Schering AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005089815-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | SCHERING AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | MCHR1 3669/4885MCHR2 2856/4885HTR4 1709/4885 |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | MCHR1 3669/4885MCHR2 2856/4885HTR4 1709/4885 |
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | MCHR1 4823/4885MCHR2 4753/4885HTR4 2802/4885 |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | MCHR1 3669/4885MCHR2 2856/4885HTR4 1709/4885 |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BRDT, AADAC, IDH2 | MCHR1 3669/4885MCHR2 2856/4885HTR4 1709/4885 |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | MCHR1 4823/4885MCHR2 4753/4885HTR4 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.